PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportspancreatic neoplasms
MeSH D010190 - pancreatic neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D010182:Pancreatic diseases
0 Companies
0 Drugs
Success rate
D004067:Digestive system neoplasms
0 Companies
0 Drugs
Success rate
D004701:Endocrine gland neoplasms
0 Companies
0 Drugs
Success rate
D010190: 
Pancreatic neoplasms
62 Companies
13 Drugs
$
Success rate
D000077779:Pancreatic intraductal neoplasms
0 Companies
0 Drugs
Success rate
D007516:Islet cell adenoma
0 Companies
0 Drugs
Success rate
D018273:Islet cell carcinoma
7 Companies
2 Drugs
$
Success rate
D021441:Pancreatic ductal carcinoma
20 Companies
1 Drug
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaFluorouracil Adrucil  1991-10-18   
Docetaxel Docetaxel  2015-09-16   
Docetaxel Docetaxel Teva  2010-01-26   
Docetaxel Docetaxel Teva Pharma  2011-01-21   
Fluorouracil Fluorouracil  2000-01-27   
Ifosfamide, Mesna Ifosfamide/mesna  2002-02-26   
Sunitinib Sunitinib  2021-11-30   
Octreotide Octreotide  2023-12-05   
Irinotecan Irinotecan  2008-02-27   
Novast LaboratoriesFluorouracil Fluorouracil  2019-12-12   
Docetaxel Docetaxel  2017-08-31   
Irinotecan Irinotecan  2017-05-26   
Taro PharmaceuticalFluorouracil Fluorouracil  2003-11-05   
IngenusDocetaxel Docetaxel 2036-03-14 2022-11-22   
MylanDocetaxel Docetaxel  2023-05-11   
Docetaxel Docetaxel Mylan  2012-01-31   
Fluorouracil Fluorouracil  2015-04-20   
Ifosfamide Ifosfamide  2012-11-26   
Octreotide Octreotide  2011-02-10   
Sunitinib Sunitinib  2021-12-06   
RocheErlotinib Tarceva  2005-09-19 $180.177 M Y2020 
SandozDocetaxel Docetaxel  2011-06-29   
Fluorouracil Fluorouracil  2011-05-02   
Irinotecan Irinotecan  2008-02-27   
NovartisEverolimus Afinitor  2009-08-02 $789 M Q2/20-Q2/23 
Octreotide Sandostatin  1988-10-21 $1,349 M Q2/20-Q2/23 
1
2
3
4
5
6
7
>
Clinical Trials
Historical Success Rate
Phase 1
70%
184/261
Phase 2
22%
62/282
Phase 3
34%
30/88
Approved: 11Overall Success rate: 5%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Docetaxel
Mylan
Docetaxel
Roche
Erlotinib,
Ado-trastuzumab emtansine,
Tiragolumab,
ETRUMADENANT,
Pegvorhyaluronidase alfa,
SELICRELUMAB,
SIMLUKAFUSP ALFA,
Retinol,
Bkt140
AstraZeneca
Tamoxifen,
Antithrombin iii,
Datopotamab deruxtecan,
Camizestrant,
Cilmostim,
Aglatimagene besadenovec,
Cediranib,
Galunisertib,
Saracatinib,
ADAVOSERTIB,
Ceralasertib,
DANVATIRSEN,
Naptumomab estafenatox,
Ds-1062
Novartis
Everolimus,
Octreotide acetate,
Octreotide,
Benzocaine,
Transplatin,
Albumin,
Antithrombin iii,
Cilmostim,
Tozadenant,
Spartalizumab,
Dovitinib,
Buparlisib,
Vatalanib,
Sodium chloride,
Retinol,
Nir178,
Lcl161,
Lgk974
Sanofi
Docetaxel,
Transplatin,
Ziv-aflibercept,
Tusamitamab ravtansine,
ALOMFILIMAB,
Larotaxel,
Retinol,
Sar-408701
Bausch Health Companies
Fluorouracil,
Antithrombin iii
Pfizer
Docetaxel,
Sunitinib,
Irinotecan hydrochloride trihydrate,
Irinotecan,
Sunitinib malate,
Irinotecan hydrochloride,
Transplatin,
Albumin,
Sasanlimab,
Aglatimagene besadenovec,
Ganitumab,
Evofosfamide,
Tacedinaline,
ULIXERTINIB,
Gedatolisib,
PONSEGROMAB
1
2
3
4
5
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use